CCL24 and metabolic dysfunction-associated steatohepatitis: Interestingly, a phase 2 A multicenter, double-blinded RCT that evaluated the safety, tolerability, and anti-fibrotic effects of CM-101 (an anti-human CCL24 monoclonal antibody) in patients with NASH has been recently completed, and its results are anticipated (ClinicalTrials.gov ID: NCT05824156).